Case reports in endocrinology
Capivasertib-Associated Diabetic Ketoacidosis With Concurrent Myocardial Injury in a Patient With Pre-Existing Coronary Artery Disease
By Noun RA, Maadarani OS and Bitar ZI.
Abstract
Capivasertib is a serine/threonine kinase AKT (AKT1-3) inhibitor, disrupting phosphorylation of AKT substrates. When combined with fulvestrant, it is approved for hormone receptor-positive advanced breast cancer. Capivasertib therapy frequently causes hyperglycemia, including diabetic ketoacidosis (DKA). Ensure glycemic control before initiation and maintain ongoing blood glucose monitoring to reduce the risk of this potentially fatal complication. We present a case of metastatic breast cancer with initially controlled blood glucose who developed ketoacidosis and myocardial infarction during capivasertib therapy.
Keywords
- capivasertib
- ischemic heart disease
- ketoacidosis
Source
Published in Case reports in endocrinology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
At a glance
More in cardiology
- Chios Mastic in Well-Controlled Hypertension: Findings From the HYPER-MASTIC Randomized Controlled TrialPharmacology research & perspectives · 2026
- Noninvasive hemodynamic estimation in patients with heart failure using electrocardiograms, pulse waves, and heart soundsComputer Methods and Programs in Biomedicine Update · 2026
